CMV Retinitis Management with Valganciclovir
Induction and Maintenance Therapy
- The Centers for Disease Control and Prevention recommends valganciclovir treatment for CMV retinitis, consisting of an induction phase of 14-21 days (900 mg twice daily) followed by lifelong maintenance therapy (900 mg once daily) until immune reconstitution occurs 1, 2, 3
- Administer valganciclovir 900 mg orally twice daily for 14-21 days as initial induction therapy, providing ganciclovir exposure comparable to intravenous ganciclovir 5 mg/kg twice daily 1, 4, 3
- Following induction, transition to valganciclovir 900 mg once daily for chronic maintenance therapy 1, 4, 3
Discontinuation Criteria
- Maintenance therapy can be safely discontinued only when CD4+ count is sustained >100-150 cells/µL for at least 3-6 months in response to antiretroviral therapy, and this decision must be made in consultation with an ophthalmologist 5, 7, 6, 2
- The CD4+ count is the primary determinant of immune recovery to CMV, not HIV viral load 5
Post-Discontinuation Monitoring
- After discontinuing maintenance therapy, patients require ophthalmologic examinations every 3 months indefinitely to detect early CMV relapse 7, 2
- Patients must be educated to report increased floaters or changes in visual acuity immediately 5, 6
Monitoring During Active Treatment
- Monitor complete blood count and renal function twice weekly during induction, then weekly during maintenance 7, 4
- Ophthalmologic examination with indirect ophthalmoscopy through dilated pupil at diagnosis, after completion of induction, at 1 month, then monthly while on treatment 7
Management of Treatment Failure or Relapse
- If retinitis progresses while on maintenance therapy, reinduction with valganciclovir 900 mg twice daily for 14-21 days is the recommended initial approach 7, 4
- Consider ganciclovir intraocular implant placement for patients who relapse on systemic therapy, as it provides superior intraocular drug levels 7, 4